세균 백신 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of bacterial vaccines Market

The global bacterial vaccines market is witnessing robust growth, supported by the rising incidence of bacterial infections, increasing immunization programs, and strong government support across regions. According to Fortune Business Insights, the global bacterial vaccines market was valued at USD 29.68 billion in 2025. The market is projected to reach USD 32.52 billion in 2026 and further expand to USD 81.35 billion by 2034, registering a CAGR of 12.14% during the forecast period. In 2025, North America dominated the market with a share of 40.97%, driven by high vaccine adoption rates and advanced healthcare infrastructure.

Bacterial vaccines are designed to protect individuals against bacterial infections by stimulating the immune system to recognize and neutralize bacterial pathogens. These vaccines play a critical role in preventing life-threatening diseases such as pneumococcal disease, meningococcal disease, diphtheria, tetanus, and pertussis. Rising awareness regarding preventive healthcare and vaccination benefits continues to accelerate global demand for bacterial vaccines.

Market Dynamics

Market Drivers

The growing incidence of bacterial diseases worldwide is a major driver of market growth. Rapid urbanization, increased population density, global travel, and migration have contributed to the spread of bacterial infections, increasing the need for effective immunization strategies. In addition, rising public awareness regarding disease prevention and expanding national immunization programs have significantly increased vaccine uptake, supporting market expansion.

Market Restraints

Regulatory hurdles present a notable restraint in the bacterial vaccines market. Vaccine development involves lengthy clinical trials, strict regulatory compliance, and high capital investment, often extending development timelines up to 10-15 years. Variations in regulatory requirements across countries further complicate global approvals and commercialization, limiting the pace of market growth.

Market Opportunities

The growing threat of antimicrobial resistance (AMR) presents a major opportunity for the bacterial vaccines market. Vaccination reduces reliance on antibiotics, thereby helping to control the emergence of drug-resistant bacterial strains. As antibiotic resistance continues to rise globally, bacterial vaccines are increasingly recognized as a preventive solution, encouraging higher investments and funding support for vaccine development.

Market Challenges

The biological complexity of bacteria poses a significant challenge for vaccine development. Unlike viruses, bacteria possess diverse antigens, making it difficult to identify targets that can generate long-lasting and protective immune responses. This complexity increases research costs and development risks, potentially limiting market growth.

Bacterial Vaccines Market Trends

A prominent trend shaping the market is the development of thermostable bacterial vaccines. These vaccines remain stable across a wide temperature range, reducing dependence on cold-chain logistics. Thermostable vaccines offer a cost-effective and practical solution, especially for emerging economies with limited infrastructure. Increasing R&D investments and ongoing clinical trials for fridge-free vaccines are expected to strengthen this trend during the forecast period.

Segmentation Analysis

By type, the recombinant/conjugate/subunit segment dominated the market in 2024, driven by its high efficacy, long-term protection, and scalable manufacturing processes. The inactivated vaccines segment held the second-largest share, supported by their safety profile and suitability for immunocompromised individuals.

By route of administration, the parenteral segment led the market in 2024, as most bacterial vaccines are injectable and provide rapid immune responses. The oral segment is expected to grow at a faster pace due to ease of administration and cost advantages.

By age group, the pediatric segment accounted for the largest share in 2024, driven by rising birth rates and expanded childhood immunization programs. The adult segment also maintained a substantial share due to increasing prevalence of bacterial infections among adults.

By indication, the pneumococcal disease segment dominated the market in 2024, supported by strong vaccination recommendations and rising disease burden. Diphtheria, tetanus, and pertussis vaccines also contributed significantly to market growth.

By distribution channel, government suppliers dominated the market in 2024, supported by large-scale procurement and vaccination campaigns led by organizations such as UNICEF and GAVI.

Regional Outlook

North America generated USD 16.55 billion in revenue in 2025, supported by strong vaccination programs and high healthcare spending.

Europe is expected to witness steady growth due to centralized procurement systems and high immunization coverage.

Asia Pacific is the fastest-growing region, driven by large population bases, government immunization initiatives, and strong vaccine manufacturing capabilities in countries such as India and China.

Latin America and the Middle East & Africa are projected to grow steadily, supported by increasing international funding and adoption of thermostable and oral vaccines.

Competitive Landscape

The bacterial vaccines market is highly consolidated, with Sanofi, GSK plc., and Merck & Co., Inc. holding a significant share. These companies focus on strong R&D pipelines, global manufacturing capabilities, and strategic collaborations. Other notable players include Bharat Biotech, Pfizer Inc., Emergent BioSolutions, and Serum Institute of India, which continue to expand their product portfolios to strengthen market presence.

Conclusion

The global bacterial vaccines market is set for substantial growth during the forecast period, driven by increasing bacterial disease burden, rising immunization coverage, and growing awareness of preventive healthcare. With the market valued at USD 29.68 billion in 2025, projected to reach USD 32.52 billion in 2026 and expand to USD 81.35 billion by 2034, continuous advancements in vaccine technology, including thermostable formulations and expanded pediatric immunization programs, are expected to shape the future landscape. Despite challenges related to regulatory complexity and bacterial diversity, sustained government support and innovation-driven strategies are anticipated to support long-term market expansion.

Segmentation By Type

• Recombinant/Conjugate/Subunit
• Inactivated
• Live Attenuated
• Toxoid
• Others

By Route of Administration

• Parenteral
• Oral

By Age Group

• Pediatrics
• Adults

By Indication

• Meningococcal Disease
• Pneumococcal Disease
• Diphtheria/Tetanus/Pertussis
• Others

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Geography

• North America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of the Asia Pacific
• Latin America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Technological Advancements in the Bacterial Vaccines
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Recombinant/Conjugate/Subunit
  • 5.1.2. Inactivated
  • 5.1.3. Live Attenuated
  • 5.1.4. Toxoid
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Parenteral
  • 5.2.2. Oral
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. Pediatrics
  • 5.3.2. Adolts
• 5.4. Market Analysis, Insights and Forecast - By Indication
  • 5.4.1. Meningococcal Disease
  • 5.4.2. Pneumococcal Disease
  • 5.4.3. Diphtheria/Tetanus/Pertussis
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital & Retail Pharmacies
  • 5.5.2. Government Suppliers
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Recombinant/Conjugate/Subunit
  • 6.1.2. Inactivated
  • 6.1.3. Live Attenuated
  • 6.1.4. Toxoid
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Parenteral
  • 6.2.2. Oral
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. Pediatrics
  • 6.3.2. Adolts
• 6.4. Market Analysis, Insights and Forecast - By Indication
  • 6.4.1. Meningococcal Disease
  • 6.4.2. Pneumococcal Disease
  • 6.4.3. Diphtheria/Tetanus/Pertussis
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital & Retail Pharmacies
  • 6.5.2. Government Suppliers
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Recombinant/Conjugate/Subunit
  • 7.1.2. Inactivated
  • 7.1.3. Live Attenuated
  • 7.1.4. Toxoid
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Parenteral
  • 7.2.2. Oral
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. Pediatrics
  • 7.3.2. Adolts
• 7.4. Market Analysis, Insights and Forecast - By Indication
  • 7.4.1. Meningococcal Disease
  • 7.4.2. Pneumococcal Disease
  • 7.4.3. Diphtheria/Tetanus/Pertussis
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital & Retail Pharmacies
  • 7.5.2. Government Suppliers
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Recombinant/Conjugate/Subunit
  • 8.1.2. Inactivated
  • 8.1.3. Live Attenuated
  • 8.1.4. Toxoid
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Parenteral
  • 8.2.2. Oral
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. Pediatrics
  • 8.3.2. Adolts
• 8.4. Market Analysis, Insights and Forecast - By Indication
  • 8.4.1. Meningococcal Disease
  • 8.4.2. Pneumococcal Disease
  • 8.4.3. Diphtheria/Tetanus/Pertussis
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital & Retail Pharmacies
  • 8.5.2. Government Suppliers
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Recombinant/Conjugate/Subunit
  • 9.1.2. Inactivated
  • 9.1.3. Live Attenuated
  • 9.1.4. Toxoid
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Parenteral
  • 9.2.2. Oral
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. Pediatrics
  • 9.3.2. Adolts
• 9.4. Market Analysis, Insights and Forecast - By Indication
  • 9.4.1. Meningococcal Disease
  • 9.4.2. Pneumococcal Disease
  • 9.4.3. Diphtheria/Tetanus/Pertussis
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital & Retail Pharmacies
  • 9.5.2. Government Suppliers
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Bacterial Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Recombinant/Conjugate/Subunit
  • 10.1.2. Inactivated
  • 10.1.3. Live Attenuated
  • 10.1.4. Toxoid
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Parenteral
  • 10.2.2. Oral
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. Pediatrics
  • 10.3.2. Adolts
• 10.4. Market Analysis, Insights and Forecast - By Indication
  • 10.4.1. Meningococcal Disease
  • 10.4.2. Pneumococcal Disease
  • 10.4.3. Diphtheria/Tetanus/Pertussis
  • 10.4.4. Others
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital & Retail Pharmacies
  • 10.5.2. Government Suppliers
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Sanofi
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. GSK plc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Bharat Biotech
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Pfizer Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Emergent BioSolutions, Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Serum Institute of india Pvt. Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. BIO-MED
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)